CANT1 Lncrna Triggers Efficient Therapeutic Efficacy by Correcting Aberrant Lncing Cascade in Malignant Uveal Melanoma.

Yue Xing,Xuyang Wen,Xia Ding,Jiayan Fan,Peiwei Chai,Renbing Jia,Shengfang Ge,Guanxiang Qian,He Zhang,Xianqun Fan
DOI: https://doi.org/10.1016/j.ymthe.2017.02.016
IF: 12.91
2023-01-01
Molecular Therapy
Abstract:Uveal melanoma (UM) is an intraocular malignant tumor with a high mortality rate. Recent studies have shown the functions of long non-coding RNAs (lncRNAs) in tumorigenesis; thus, targeting tumor-specific lncRNA abnormalities has become an attractive approach for developing therapeutics to treat uveal melanoma. In this study, we identified a novel nuclear CANT1 lncRNA (CASC15-New-Transcript 1) that acts as a necessary UM suppressor. CANT1 significantly reduced tumor metastatic capacity and tumor formation, either in cell culture or in animals harboring tumor xenograft. Intriguingly, XIST lncRNA serves as a potential target of CANT1, and JPX or FTX lncRNA subsequently serves as a contextual hinge to activate a novel CANT1-JPX/FTX-XIST long non-coding (lncing) pathway in UM. Moreover, CANT1 triggers the expression of JPX and FTX by directly binding to their promoters and promoting H3K4 methylation. These observations delineate a novel lncing cascade in which lncRNAs directly build a lncing cascade without coding genes that aims to modulate UM tumorigenesis, thereby specifying a novel "lncing-cascade renewal" anti-tumor therapeutic strategy by correcting aberrant lncing cascade in uveal melanoma.
What problem does this paper attempt to address?